Tonix Pharmaceuticals Holding Corp. (TNXP): restructuring charge — Tonix expects $50M non-cash impairment on decommissioned ADC facility in Q2 2024

Tonix Pharmaceuticals Holding Corp.

Non-cash impairment charge of ~$50M to be recognized in Q2 2024 financial statements.
Facility is a 45,000 sq ft bio-safety level-2 plant in Dartmouth, MA, previously intended for live-virus vaccine manufacturing.
Impairment assumes general industrial use, not GMP; equipment appraised; brokerage firm retained to find buyer.
Company states impairment will not affect future operations, liquidity, or cash flows.
Decommissioning aligns with strategic focus on Tonmya (TNX-102 SL) for fibromyalgia.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Tonix Pharmaceuticals Holding Corp. announced a impairment with charges of approximately $50 million affecting Advanced Development Center in Dartmouth, Massachusetts.

Type: impairment
Charge: approximately $50 million
Affected area: Advanced Development Center in Dartmouth, Massachusetts

Exact text from the filing

the Company expects that the financial statements for the quarter ended June 30, 2024 will reflect a non-cash impairment in the amount of approximately $50 million

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-24-009003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.